The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)
 
Benedito A. Carneiro
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Ariel E. Birnbaum
No Relationships to Disclose
 
Matthew H. Taylor
Honoraria - Bayer; Bristol Myers Squibb Foundation; Eisai; Merck; Pfizer; Regeneron; Roche
Consulting or Advisory Role - Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Sanofi
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Loxo/Bayer (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
 
Shetal Arvind Patel
Research Funding - BeiGene (Inst); Dracen (Inst); Macrogenics (Inst); Seagen (Inst); Shattuck Labs (Inst)
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Roche/Genentech
 
Bokai Wang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Francisco Beca
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Shweta Jain
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Ibrahima Soumaoro
Employment - Genmab
Stock and Other Ownership Interests - Bristol-Myers Squibb; Genmab
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune